ARWR logo

Arrowhead Pharmaceuticals, Inc.

ARWR
Healthcare|Biotechnology|US
$58.16
+0.70 (+1.22%)
Tangible Book / Share
$3.21
Cash / Share
$11.17

Financials

Financial Snapshot

Market Cap
$8.22B
Enterprise Value
$9.02B
Revenue (TTM)
$669.5M
Net Income (TTM)
-$320.0M
Cash & Investments
$1.60B
Net Cash
$737.9M
Free Cash Flow (TTM)
-$75.1M
Operating CF (TTM)
-$59.1M
Debt/Equity
1.86

Cash Runway & Burn Rate

Cash on Hand
$1.60B
Quarterly Burn
$14.8M
Monthly Burn
$4.9M
Est. Runway
~108.5 quarters
MetricTrend2016201720182019202020212022202320242025TTM
Cash & Investments
$85.4M$65.6M$76.5M$258.7M$315.5M$367.8M$376.4M$403.6M$681.0M$919.4M$1.60B
Operating Cash Flow
-$64.4M-$23.9M-$47.2M$173.0M-$95.8M$171.3M-$136.1M-$153.9M-$462.9M$179.6M-$59.1M
Free Cash Flow
-$68.3M-$31.9M-$48.6M$161.0M-$107.8M$147.7M-$188.9M-$330.6M-$604.3M$156.9M-$75.1M
Capital Expenditure
-$3.9M-$7.9M-$1.4M-$12.0M-$12.0M-$23.6M-$52.8M-$176.7M-$141.5M-$22.7M-$16.1M
Financing Cash Flow
$55.1M$12.1M$60.0M$66.4M$257.9M$11.3M$65.2M$253.1M$870.5M$74.0M$784.2M

R&D Spending

R&D (TTM)
$723.4M
R&D Intensity
108.0%
R&D Growth vs Prior
+19.1%
MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$158.3K$31.4M$16.1M$168.8M$88.0M$138.3M$243.2M$240.7M$3.6M$829.4M$669.5M
R&D Expense
$41.5M$46.3M$48.3M$76.6M$123.5M$206.3M$288.5M$342.3M$489.2M$607.2M$723.4M
R&D % of Revenue
26181.8%147.3%299.2%45.4%140.4%149.2%118.6%142.2%13776.9%73.2%108.0%
SG&A
$23.6M$17.5M$19.1M$26.5M$52.3M$81.0M$124.4M$90.9M$96.8M$121.9M$171.1M

Income Statement

MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$158.3K$31.4M$16.1M$168.8M$88.0M$138.3M$243.2M$240.7M$3.6M$829.4M$669.5M
Cost of Revenue
$0.00$0.00$0.00$0.00$0.00$0.00$10.4M$12.5M$18.6M$0.00$0.00
Gross Profit
$0.00$0.00$0.00$0.00$0.00$138.3M$232.8M$228.2M-$15.0M$829.4M$669.5M
R&D
$41.5M$46.3M$48.3M$76.6M$123.5M$206.3M$288.5M$342.3M$489.2M$607.2M$723.4M
SG&A
$23.6M$17.5M$19.1M$26.5M$52.3M$81.0M$124.4M$90.9M$96.8M$121.9M$171.1M
Operating Income
-$81.7M-$37.0M-$55.9M$61.2M-$93.2M-$149.0M-$178.5M-$205.0M-$601.1M$98.3M-$226.4M
Interest Expense
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$18.3M$32.4M$89.4M$92.6M
Pretax Income
-$81.7M-$34.4M-$54.4M$68.1M-$84.6M-$140.8M-$172.7M-$206.5M-$612.5M$51.5M-$252.1M
Net Income
-$81.7M-$34.4M-$54.5M$68.0M-$84.6M-$140.8M-$176.1M-$205.3M-$599.5M-$1.6M-$320.0M
EPS (Diluted)
-1.34-0.47-0.650.69-0.84-1.36-1.67-1.92-5.00-0.01-2.24
EBITDA
-$76.4M-$32.3M-$51.2M$65.6M-$87.2M-$132.6M-$162.3M-$175.7M-$561.5M$164.8M-$133.7M
Shares Out. (M)
61.0573.9083.6498.61100.72103.74105.43106.75119.78133.76143.38

Balance Sheet

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Equivalents
$85.4M$24.8M$30.1M$221.8M$143.6M$184.4M$108.0M$110.9M$102.7M$226.5M$54.8M
Short-Term Investments
$0.00$40.8M$46.4M$36.9M$171.9M$183.4M$268.4M$292.7M$578.3M$692.8M$1.55B
Total Current Assets
$90.5M$67.9M$78.8M$265.2M$322.4M$384.6M$405.3M$419.5M$695.5M$950.6M$1.67B
Total Assets
$128.2M$104.0M$111.6M$349.8M$522.5M$710.1M$691.9M$765.6M$1.14B$1.39B$2.11B
Total Current Liabilities
$25.6M$18.7M$12.4M$97.1M$40.7M$146.5M$138.8M$105.5M$103.2M$195.5M$283.3M
Long-Term Debt
$2.5M$2.3M$2.1M$0.00$0.00$0.00$0.00$268.3M$734.5M$214.9M$824.1M
Total Liabilities
$33.2M$23.2M$16.4M$105.8M$60.7M$301.3M$273.6M$478.4M$948.7M$881.9M$1.65B
Stockholders' Equity
$95.6M$81.4M$95.8M$244.6M$461.8M$408.8M$398.5M$271.3M$185.4M$466.1M$465.5M
Retained Earnings
-$398.4M-$432.8M-$487.3M-$419.3M-$503.8M-$644.7M-$820.8M-$1.03B-$1.63B-$1.63B-$1.92B

Cash Flow Statement

MetricTrend2016201720182019202020212022202320242025TTM
Operating Cash Flow
-$64.4M-$23.9M-$47.2M$173.0M-$95.8M$171.3M-$136.1M-$153.9M-$462.9M$179.6M-$59.1M
Capital Expenditure
-$3.9M-$7.9M-$1.4M-$12.0M-$12.0M-$23.6M-$52.8M-$176.7M-$141.5M-$22.7M-$16.1M
Free Cash Flow
-$68.3M-$31.9M-$48.6M$161.0M-$107.8M$147.7M-$188.9M-$330.6M-$604.3M$156.9M-$75.1M
Investing Cash Flow
$13.4M-$48.6M-$7.4M-$47.7M-$240.8M-$141.7M-$5.4M-$96.2M-$420.1M-$129.3M-$801.7M
Financing Cash Flow
$55.1M$12.1M$60.0M$66.4M$257.9M$11.3M$65.2M$253.1M$870.5M$74.0M$784.2M
Issuance of Stock
$52.2M$12.4M$56.6M$60.5M$250.5M$0.00$5.2M$3.1M$431.7M$270.4M$303.9M
Repurchase of Stock
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Net Debt Issuance
-$217.5K-$197.8K-$208.5K-$2.4M$0.00$0.00$0.00$0.00$392.0M-$191.4M$1.19B
Stock Based Comp.
$11.6M$7.9M$8.5M$12.4M$43.4M$76.7M$120.9M$78.1M$74.0M$63.4M$70.0M
Net Change in Cash
$4.2M-$60.5M$5.3M$191.7M-$78.2M$40.9M-$76.4M$2.9M-$8.2M$123.9M-$75.0M

Dilution Tracker

Shares outstanding grew 32.8% over 5 years — significant dilution
Shares Outstanding
141M
5-Year Share Growth
+32.8%
Stock Issuance (TTM)
$303.9M
MetricTrend2016201720182019202020212022202320242025TTM
Shares Out. (M)
61.0573.9083.6498.61100.72103.74105.43106.75119.78133.76143.38
Change vs Prior %
—21.0%13.2%17.9%2.1%3.0%1.6%1.3%12.2%11.7%7.2%
Stock Issuance
$52.2M$12.4M$56.6M$60.5M$250.5M$0.00$5.2M$3.1M$431.7M$270.4M$303.9M
Stock Repurchase
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Stock Based Comp.
$11.6M$7.9M$8.5M$12.4M$43.4M$76.7M$120.9M$78.1M$74.0M$63.4M$70.0M

Margins & Profitability

MetricTrend2016201720182019202020212022202320242025TTM
Gross Margin %
0.0%0.0%0.0%0.0%0.0%100.0%95.7%94.8%-423.7%100.0%100.0%
Operating Margin %
-51627.1%-117.8%-346.5%36.3%-105.9%-107.8%-73.4%-85.2%-16927.1%11.9%-33.8%
Net Margin %
-51614.6%-109.5%-337.3%40.3%-96.1%-101.9%-72.4%-85.3%-16882.4%-0.2%-47.8%
EBITDA Margin %
-48272.9%-102.9%-317.4%38.9%-99.1%-95.9%-66.7%-73.0%-15812.8%19.9%-20.0%
FCF Margin %
-43129.2%-101.4%-301.3%95.4%-122.5%106.8%-77.7%-137.3%-17018.3%18.9%-11.2%
ROE %
-85.5%-42.2%-56.8%27.8%-18.3%-34.5%-44.2%-75.7%-323.3%-0.3%-60.5%
ROA %
-63.8%-33.1%-48.8%19.4%-16.2%-19.8%-25.4%-26.8%-52.6%-0.1%-15.1%
ROIC %
-79.6%-43.3%-56.2%24.1%-19.3%-26.3%-32.1%-30.6%-57.4%4.6%-12.1%
R&D / Revenue %
26181.8%147.3%299.2%45.4%140.4%149.2%118.6%142.2%13776.9%73.2%108.0%

Growth (Year over Year)

Fiscal years. Rising share count growth means dilution.

MetricTrend2016201720182019202020212022202320242025
Revenue
-58.6%19736.5%-48.6%945.7%-47.9%57.2%75.9%-1.0%-98.5%23258.2%
Gross Profit
0.0%0.0%0.0%0.0%0.0%0.0%68.4%-2.0%-106.6%5613.5%
Operating Income
14.8%54.7%-51.2%209.4%-252.2%-60.0%-19.8%-14.8%-193.2%116.4%
Net Income
11.1%57.9%-58.4%224.8%-224.4%-66.6%-25.0%-16.6%-192.0%99.7%
EPS (Diluted)
16.3%64.9%-38.3%206.2%-221.7%-61.9%-22.8%-15.0%-160.4%99.8%
Operating Cash Flow
1.9%62.8%-97.3%466.4%-155.4%278.8%-179.5%-13.0%-200.8%138.8%
Free Cash Flow
-0.9%53.3%-52.7%431.0%-166.9%237.1%-227.9%-75.0%-82.8%126.0%
R&D Expense
-12.3%11.6%4.4%58.7%61.2%67.0%39.8%18.7%42.9%24.1%
SG&A Expense
-32.0%-26.0%9.3%39.1%97.0%54.9%53.7%-26.9%6.5%25.9%
Total Assets
-3.1%-18.8%7.3%213.5%49.4%35.9%-2.6%10.6%48.9%21.5%
Book Value / Share
-18.5%-29.0%3.0%128.3%76.3%-14.0%0.7%-32.2%-40.7%136.0%
Debt
259.7%-7.1%-8.2%-100.0%0.0%20.8%219.3%370.1%122.1%-57.0%
Diluted Shares
6.4%21.0%13.2%17.9%2.1%3.0%1.6%1.3%12.2%11.7%

Valuation

P/E (TTM)At Loss
P/S12.27
10Y Low / Med / High5.56 / 46.84 / 2831.10
P/B17.91
10Y Low / Med / High3.89 / 10.57 / 16.77
EV/EBITDAAt Loss
EV/Revenue13.48
10Y Low / Med / High5.73 / 45.69 / 2309.17
P/FCFAt Loss
10Y Low / Med / High16.42 / 29.41 / 43.84

Intrinsic Value Models (per share)

Tangible Book / Share
$3.21
Net Current Assets / Share
$0.18
Cash / Share
$11.17
MetricTrend2016201720182019202020212022202320242025TTM
P/E Ratio
-5.49-9.21-29.5539.14-51.26-45.90-19.79-13.99-3.87-2827.05-25.96
P/S Ratio
2831.1010.0899.5315.6749.2946.8414.3311.92653.405.5612.27
P/B Ratio
4.693.8916.7710.819.3915.848.7410.5712.519.9017.91
EV/EBITDA
-4.78-9.11-30.8236.92-48.32-47.65-21.31-17.88-5.4728.84-67.52
EV/Revenue
2309.179.3797.8114.3647.9045.6914.2213.05864.395.7313.48

Analyst Estimates & Quality

Altman Z-Score
2.58
Grey Zone
Piotroski F-Score
3
Weak

Forward Estimates (consensus)

MetricFY2027FY2028FY2029
Revenue$330.1M$666.1M$1.15B
Net Income-$710.2M-$461.7M-$178.3M
EPS$-4.86$-2.81$-0.74
# Analysts (EPS)1385